Vyalev — Net revenues
AbbVie Vyalev — Net revenues increased by 9.8% to $201M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 219.0%, from $63M to $201M. Over 2 years (FY 2023 to FY 2025), Vyalev — Net revenues shows an upward trend with a 1167.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and growing physician adoption of the therapy, while a decrease may signal competitive pressure or challenges in patient access.
Detailed definition
This metric represents the total gross sales of the Vyalev product line minus returns, allowances, and rebates. It serve...
Peer comparison
Comparable to revenue metrics for specific high-growth pharmaceutical assets or newly launched specialty drugs at peer biopharmaceutical companies.
abbv_segment_vyalev_net_revenuesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $750K | $750K | $750K | $750K | $9M | $18M | $28M | $44M | $63M | $98M | $138M | $183M | $201M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +100.0% | +55.6% | +57.1% | +43.2% | +55.6% | +40.8% | +32.6% | +9.8% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | +600.0% | +444.4% | +392.9% | +315.9% | +219.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's vyalev — net revenues?
- AbbVie (ABBV) reported vyalev — net revenues of $201M in Q1 2026.
- How has AbbVie's vyalev — net revenues changed year-over-year?
- AbbVie's vyalev — net revenues increased by 219.0% year-over-year, from $63M to $201M.
- What is the long-term trend for AbbVie's vyalev — net revenues?
- Over 2 years (2023 to 2025), AbbVie's vyalev — net revenues has grown at a 1167.5% compound annual growth rate (CAGR), from $3M to $482M.
- What does vyalev — net revenues mean?
- The total revenue generated from the sales of the Vyalev product line.